Jason M. Broderick

"This is one of very few studies in advanced squamous NSCLC that has shown median survival beyond 2 years," said Shun Lu, MD, PhD.

"Dedifferentiated liposarcoma is usually treated with surgery, but when it comes back, it is difficult to treat and often incurable," said Mark Dickson, MD.

"These findings may be considered practice changing for medical oncologists treating HCC globally,” said Vishwanath Sathyanarayanan, MD.

"Early molecular testing is critically important now in these [patients with] mCSPC,” said TALAPRO-3 lead investigator Neeraj Agarwal, MD, FASCO.

"I think the [PROTEUS] study will change the standard of care for many patients who are candidates for surgery and have high-risk localized prostate cancer,” said William K. Oh, MD.

“The results support daraxonrasib as the new standard of care for patients with previously treated metastatic PDAC,” said Brian Wolpin, MD.

"Adjuvant selpercatinib should be considered as a new standard of care in early-stage RET fusion–positive lung cancer,” said Jonathan Goldman, MD.

“This study is important in that it represents a potential therapy option for patients in resource-limited parts of the world," said Glenn J. Hanna, MD.

“MajesTEC-9 is the second phase 3 study to show a significant PFS and OS benefit in the second-line setting and beyond with teclistamab-based therapy for RRMM,” said Roberto Mina, MD.

"The key finding is that more axillary surgery in itself does not improve survival in these patients," said Jana de Boniface, MD, PhD.

Notably, patients in EV-302 who converted from PR to CR achieved survival outcomes similar to those who achieved CR directly.

ROSELLA update shows consistent OS benefit with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, irrespective of prior taxane use.

The phase 3 POTOMAC study was the supporting trial for the FDA approval of the durvalumab combination for BCG-naive NMIBC.

Treatment with the ADC pivekimab sunirine can be initiated in an outpatient setting.

The approval of the TROP2-directed ADC datopotamab deruxtecan is supported by results from the phase 3 TROPION-Breast02 trial.

The results strengthen the evidence base for imetelstat's benefit in this high-risk, post-ruxolitinib myelofibrosis population.

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts shaping care.

Patients with high-risk myelodysplastic syndrome received the novel anti-IL1RAP antibody nadunolimab combined with azacitidine.

The sBLA for nogapendekin alfa inbakicept is supported by 36-month follow-up data from cohort B of the QUILT-3.032 trial.

Long-term real-world safety and effectiveness of darbepoetin alfa in MDS-related anemia are consistent with registration trial findings.

Investigators urge caution in interpreting these results, acknowledging the inherent limitations of unanchored, population-adjusted indirect trial comparisons.

The TRITON3 update supports rucaparib's role as an established option in the post-ARPI, pre-chemotherapy BRCA+ mCRPC setting.

"Sac-TMT may be able to address a critical unmet need for certain patients with advanced endometrial cancer," said Domenica Lorusso, MD, PhD.

The neoadjuvant and adjuvant FDA indications for T-DXd in HER2+ breast cancer are based on the DESTINY-Breast11 and DESTINY-Breast05 trials, respectively.

In ARASEC, darolutamide plus ADT significantly improved survival and disease control versus ADT alone in mHSPC, complementing ARANOTE outcomes.

The FDA approved atezolizumab for the adjuvant treatment of muscle invasive bladder cancer with ctDNA molecular residual disease after cystectomy.

UGN-103 (mitomycin) for intravesical solution sustained disease control through 6 months in the UTOPIA trial in recurrent intermediate-risk LG-NMIBC.

The FDA has granted suplexa, a non-engineered autologous cellular immunotherapy, fast track designation for patients with MSI-H colorectal cancer.

The phase 3 VOLGA trial showed perioperative durvalumab plus neoadjuvant enfortumab vedotin reduced the risk of death in muscle-invasive bladder cancer.

Mitomycin for intravesical solution demonstrated durable responses in 36-month follow-up data from the phase 3 ENVISION trial.